| Year |
Citation |
Score |
| 2022 |
LoRusso P, Ratain MJ, Doi T, Rasco DW, de Jonge MJA, Moreno V, Carneiro BA, Devriese LA, Petrich A, Modi D, Morgan-Lappe S, Nuthalapati S, Motwani M, Dunbar M, Glasgow J, et al. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Investigational New Drugs. PMID 35467243 DOI: 10.1007/s10637-022-01247-1 |
0.37 |
|
| 2020 |
Lemech C, Woodward N, Chan N, Mortimer J, Naumovski L, Nuthalapati S, Tong B, Jiang F, Ansell P, Ratajczak CK, Sachdev J. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Investigational New Drugs. PMID 32524319 DOI: 10.1007/s10637-020-00960-z |
0.337 |
|
| 2017 |
Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, et al. A Phase 1 Dose-Escalation Study of Single-Agent Veliparib in Japanese Patients with Advanced Solid Tumors. Cancer Science. PMID 28665051 DOI: 10.1111/cas.13307 |
0.324 |
|
| 2012 |
Nuthalapati S, Zhou Q, Guo P, Lv H, Cosenza S, Reddy MV, Reddy EP, Gallo JM. Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy. Pharmaceutical Research. 29: 2499-511. PMID 22678771 DOI: 10.1007/S11095-012-0780-Y |
0.321 |
|
| 2007 |
Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. The Journal of Pharmacology and Experimental Therapeutics. 321: 265-75. PMID 17259446 DOI: 10.1124/Jpet.106.118265 |
0.319 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2016 |
Munasinghe W, Stodtmann S, Tolcher A, Calvo E, Gordon M, Jalving M, de Vos-Geelen J, Medina D, Bergau D, Nuthalapati S, Hoffman D, Shepherd S, Xiong H. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study. Cancer Chemotherapy and Pharmacology. PMID 27709282 DOI: 10.1007/s00280-016-3156-x |
0.286 |
|
| 2017 |
Nishio S, Takekuma M, Takeuchi S, Kawano K, Tsuda N, Tasaki K, Takahashi N, Abe M, Tanaka A, Nagasawa T, Shoji T, Xiong H, Nuthalapati S, Leahy T, Hashiba H, et al. A phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. Cancer Science. PMID 28837250 DOI: 10.1111/cas.13381 |
0.283 |
|
| 2018 |
Atrafi F, Groen HJ, Byers LA, Garralda E, Lolkema M, Sangha R, Viteri S, Chae YK, Camidge DR, Gabrail N, Hu B, Tian T, Nuthalapati S, Hoening E, He L, et al. A Phase 1 Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30327308 DOI: 10.1158/1078-0432.CCR-18-2014 |
0.28 |
|
| 2011 |
Nuthalapati S, Guo P, Zhou Q, Reddy MV, Reddy EP, Gallo JM. Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. Journal of Pharmaceutical and Biomedical Analysis. 56: 1117-20. PMID 21880454 DOI: 10.1016/J.Jpba.2011.08.003 |
0.278 |
|
| 2017 |
Nuthalapati S, Munasinghe W, Giranda V, Xiong H. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. Clinical Pharmacokinetics. PMID 28497258 DOI: 10.1007/s40262-017-0547-z |
0.272 |
|
| 2017 |
Mittapalli RK, Nuthalapati S, Shepherd SP, Xiong H. Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer. Cancer Chemotherapy and Pharmacology. PMID 28247011 DOI: 10.1007/s00280-017-3262-4 |
0.265 |
|
| 2019 |
Nuthalapati S, Stodtmann S, Shepherd SP, Ratajczak CK, Mensing S, Menon R, Xiong H. Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients. Cancer Chemotherapy and Pharmacology. PMID 31468137 DOI: 10.1007/s00280-019-03930-2 |
0.241 |
|
| 2021 |
Stodtmann S, Nuthalapati S, Eckert D, Kasichayanula S, Joshi R, Bach BA, Mensing S, Menon R, Xiong H. A Population Pharmacokinetic Meta-analysis of Veliparib, a PARP Inhibitor, Across Phase I/II/III Trials in Cancer Patients. Journal of Clinical Pharmacology. PMID 33894017 DOI: 10.1002/jcph.1875 |
0.24 |
|
| 2021 |
Clarke JM, Patel JD, Robert F, Kio EA, Thara E, Ross Camidge D, Dunbar M, Nuthalapati S, Dinh MH, Bach BA. Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. Lung Cancer (Amsterdam, Netherlands). 161: 180-188. PMID 34607210 DOI: 10.1016/j.lungcan.2021.09.004 |
0.216 |
|
| 2018 |
Marroum PJ, Nuthalapati S, Parikh A, Shebley M, Hoffman D, Zha J, Khatri A, Awni WM. Industry Perspective on Standardizing Food-Effect Studies for New Drug Development. Clinical Pharmacokinetics. PMID 29460023 DOI: 10.1007/S40262-018-0630-0 |
0.163 |
|
| 2022 |
Stodtmann S, Eckert D, Joshi R, Nuthalapati S, Ratajczak CK, Menon R, Mensing S, Xiong H. An Exposure-Response Model with Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial. Journal of Clinical Pharmacology. PMID 35403245 DOI: 10.1002/jcph.2061 |
0.163 |
|
| 2016 |
Salem AH, Agarwal S, Dunbar M, Nuthalapati S, Chien D, Freise KJ, Wong SL. Effect of Low and High Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class Bcl-2 Inhibitor. Journal of Clinical Pharmacology. PMID 27029823 DOI: 10.1002/Jcph.741 |
0.161 |
|
| 2022 |
Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, ... ... Nuthalapati S, et al. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102188. PMID 35180010 DOI: 10.1200/JCO.21.02188 |
0.15 |
|
| 2017 |
Mittapalli RK, Nuthalapati S, Delke DeBord AE, Xiong H. Development of a Level a in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation. Pharmaceutical Research. PMID 28243955 DOI: 10.1007/s11095-017-2133-3 |
0.079 |
|
| 2024 |
Mohamed MF, Girish S, Humeniuk R, Nuthalapati S, Desai A, Datta-Mannan A, Gheyas F, Kanodia J, Cheeti S, Zhu T. Impact of COVID-19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective. Clinical Pharmacology and Therapeutics. PMID 38536001 DOI: 10.1002/cpt.3242 |
0.045 |
|
| Hide low-probability matches. |